This week, Senators Tom Cotton, R-Arkansas, and Claire McCaskill, D-Missouri introduced the Preserving Access to Cost-Effective Drugs (PACED) Act in response to Allergan’s recent transfer of its patents covering its dry-eye drug, Restasis, to the Saint Regis Mohawk Tribe in exchange for the Tribe’s invocation of sovereign immunity against inter partes review.
This week, Senators Tom Cotton, R-Arkansas, and Claire McCaskill, D-Missouri, introduced the Preserving Access to Cost-Effective Drugs or PACED Act in response to Allergan’s recent transfer of its patents covering its dry-eye drug, Restasis, to the Saint Regis Mohawk Tribe in exchange for the Tribe’s invocation of sovereign immunity against inter partes review.
While the US Patent Trial and Appeal Board (PTAB) ultimately decided that the Tribe could not claim sovereign immunity in this case, Allergan’s unusual gambit to protect its market share—and the Tribe’s motion to seek discovery into the internal workings of the PTAB itself—sparked ire among lawmakers and other pharmaceutical industry stakeholders who feared that other drug makers would follow in Allergan’s footsteps, essentially insulating their high-earning innovator products from competition from generic or biosimilar drugs.
According to Cotton, "It's far past time that we crack down on patent abuse, which is raising costs for our seniors,” and the newly introduced bill “will make sure unscrupulous patent holders can't game the system and block their competitors from entering the market. That'll go a long way to help seniors get the drugs they need.”
"We watched a company brazenly try to exploit a potential legal loophole to game the system in an effort to protect their bottom line,” added McCaskill. “That should be illegal, and our bipartisan bill would make it so by ending this astounding assertion of sovereign immunity to avoid patent review, before any other companies follow suit."
The bipartisan bill would amend title 35 of the United States Code to provide that a patent owner may not assert sovereign immunity as a defense in actions before the United States Patent and Trademark Office. In cases in which foreign states are the owners of patents, the PTAB will make the determination of whether the owner is immune from the PTAB’s jurisdiction. Under the proposed law, in any action involving a patent claim that is otherwise within the jurisdiction of the United States, a tribe may not assert sovereign immunity as a defense.
The bill has support of organizations including America’s Health Insurance Plans, the Association for Accessible Medicines, Patients for Affordable Drugs Now, and the BlueCross BlueShield Association.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.